Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;206(4):1062-1066.
doi: 10.1111/bjh.20037. Epub 2025 Mar 4.

Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment

Andrew B Song  1   2 , Hanny Al-Samkari  1   2
Affiliations
Review

Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment

Andrew B Song et al. Br J Haematol. 2025 Apr.

Abstract

Chemotherapy-induced thrombocytopenia (CIT) is a common clinical problem in patients with solid tumour malignancies. Unlike nadir CIT which often resolves by the start of the following chemotherapy cycle, persistent CIT results in unacceptably low platelet counts at the beginning of a cycle lasting throughout multiple chemotherapy cycles, resulting in bleeding as well as chemotherapy treatment delays, dose reductions and discontinuation. Persistent CIT can be managed with thrombopoietin receptor agonist support in the context of a clinical trial or off-label use of romiplostim if a trial is not available.

Keywords: CIT; TPO‐RA; avatrombopag; chemotherapy; chemotherapy‐induced thrombocytopenia; romiplostim; thrombocytopenia; thrombopoietin; thrombopoietin receptor agonist.

PubMed Disclaimer

References

    1. Al-Samkari H Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood Rev. 2024;63:101139. - PMC - PubMed
    1. Song AB, Rosovsky RP, Connors JM, Al-Samkari H. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. Vasc Health Risk Manag. 2019;15:175–186. - PMC - PubMed
    1. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137–1146. - PubMed
    1. Nakayama G, Tanaka C, Uehara K, et al. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2014;73(4):847–855. - PubMed
    1. Al-Samkari H Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. Hematology Am Soc Hematol Educ Program. 2022;2022(1):286–295. - PMC - PubMed

MeSH terms

LinkOut - more resources